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We systematically compare X-ray structures of
inhibitor complexes of four well-known enzymes
and correlate two- and three-dimensional (2D
and 3D) similarity of inhibitors with their po-
tency. The analysis reveals the presence of
unexpected systematic relationships between
molecular similarity and potency. These
findings explain why apparently inconsistent
structure-activity relationships (SARs) can
coexist in different targets, and they have
general implications for compound screening
and optimization. The results suggest that (1)
even for active sites with significant bind-
ing constraints, there is a high probability
that structurally diverse ligands with similar
activity can be identified, (2) different types
of SARs are not mutually exclusive, and (3)
the chemical nature of ligands is of compara-
ble importance for SARs as the features of
active sites. These insights aid in the under-
standing of target-specific SARs and their
intrinsic degree of variability.
INTRODUCTION
Understanding the relationship between the similarity and
biological specificity of small molecules is of paramount
importance for drug design and chemical biology [1–5].
Specific binding of small molecules to target proteins is
generally characterized by a high degree of molecu-
lar complementarity including specific interactions and
shape [4]. How these binding characteristics might gener-
ally affect the nature of ligand structure-activity relation-
ships (SARs) is unknown. Open questions include, for
example: Do structural features of target sites ‘‘dictate’’
SARs? Are different types of SARs mutually exclusive?
Is ligand similarity related to SAR characteristics?
Importantly, the study of SARs is complicated by
a widely recognized conundrum: on the one hand, small
structural modifications of active molecules often haveChemistry & Biology 14,dramatic effects on selectivity and/or potency [6]. There-
fore, we call the underlying SARs ‘‘discontinuous.’’ On
the other hand, a spectrum of similar molecules is often
found to have similar activity [5], and, in addition, increas-
ingly structurally diverse compounds can be active
against the same target [5, 7]. Accordingly, the underlying
SARs are termed ‘‘continuous.’’ Discontinuous SARs are
explored in chemical lead optimization [6], whereas con-
tinuous SARs are investigated in molecular-similarity anal-
ysis [5], small-molecule-based virtual screening [7], or
‘‘scaffold hopping’’ [8]. Although principal differences
between SAR characteristics are long known [5], potential
relationships between continuous and discontinuous
SARs have remained largely unclear.
In our analysis, we have evaluated SAR characteristics
in detail with the aid of experimental structural and binding
data and different molecular representations for the eval-
uation of similarity. We have compared the crystal struc-
tures of complexes of well-known enzymes with different
inhibitors and correlated the 2D and 3D similarity of bound
inhibitors with their potency. The analysis reveals system-
atic and, in part, unexpected relationships between simi-
larity and potency and the coexistence of different
target-specific SARs within an activity landscape. This
helps to rationalize why molecular-similarity methods
often succeed in identifying novel active molecules [5,
7]. Furthermore, variations in 2D structure do not always
constrain the ability of ligands to adopt diverse binding
modes, which has important implications for drug design.
RESULTS AND DISCUSSION
On the basis of a survey of the PDBbind database [9, 10],
we selected four enzymes for our analysis: two serine
proteases, elastase and coagulation factor Xa; carbonic
anhydrase II; and ribonuclease A. The wealth of structural
data available for these enzymes is a consequence of the
fact that they are long-established targets. In addition,
these test cases represent active sites of distinctly differ-
ent architectures and chemical features. Figure 1 shows
the enzyme structures and active-site regions, and Table
S1 (see the Supplemental Data available with this article
online) summarizes the structural data used for our analy-
sis. We have systematically compared the 2D similarity of489–497, May 2007 ª2007 Elsevier Ltd All rights reserved 489
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Heterogeneous SARs and Variable Activity LandscapesFigure 1. Structures of Enzyme Targets
and Their Active Site Regions
For each of the four enzymes studied here,
a representative X-ray structure of an inhibitor
complex is shown (with its PDB ID code). Ac-
tive sites are rendered in solid surface repre-
sentations and are colored by partial charge
distributions (gold, negative; blue, positive).
When atom coloring is used for inhibitors, the
same color scheme is applied in all represen-
tations: carbon, gray; oxygen, red; nitrogen,
blue; sulfur, yellow; phosphorus, magenta;
halogens, green.inhibitors with their 3D similarity (determined by binding
conformation, position, and orientation), quantitatively as-
sessed similarity relationships, and related these relation-
ships to differences in compound potency. There are no
absolute measures of molecular similarity, and any evalu-
ation of similarity depends on the molecular representa-
tions that are employed (as described in Experimental
Procedures). However, similarity relationships discussed
in our study can also be qualitatively appreciated by com-
paring the 2D molecular graphs and 3D structural views
that we present.
The active sites of ribonuclease A and carbonic anhy-
drase II pose severe structural constraints on ligand bind-
ing. Ribonuclease A cleaves single-stranded RNA and
accommodates a phosphate group in a positively charged
phosphate-binding pocket (Figure S1). Filling this pocket
and compensating the positively charged residues is
a prerequisite for inhibitor binding, which makes this
enzyme a model system for SARs that are discontinuous
in nature and largely determined by the presence of an
‘‘activity cliff’’ [11]. Accordingly, known inhibitors are nu-
cleotide analogs with one or more phosphate group and
typically have very similar structures (Figure 2A) that
have Tanimoto similarity between MACCS structural key
representations greater than 0.75 (for an explanation,
see Experimental Procedures). Although these inhibitors
have very similar 2D structures, there are significant 3D
variations (Figure 2A) because inhibitors containing differ-
ent bases bind in different conformations and orientations.
In fact, as illustrated in Figure 2B, similar structures can
bind very differently as long as the phosphate group con-
straint is satisfied. Furthermore, there is little correlation490 Chemistry & Biology 14, 489–497, May 2007 ª2007 Elseviebetween structural similarity and compound potency.
Similar structures have different potency levels irrespec-
tive of whether their binding modes are similar or not.
Thus, although the underlying SAR looks very simple at
the 2D level, there is significant variation among ribonucle-
ase A inhibitor-binding modes. Moreover, inhibitors with
nearly identical binding conformations can differ by up
to three orders of magnitude in potency, as illustrated in
Figure 2C. As a prototype for discontinuous SARs, ribonu-
clease A is surprisingly flexible in its accommodation of
different binding modes.
In carbonic anhydrase II, the need to coordinate a cata-
lytically important zinc cation within the active site pres-
ents the major constraint for inhibitor binding (Figure S2),
and sulfonamide groups are a hallmark of carbonic anhy-
drase inhibitors, contributing several orders of magnitude
to potency (Figure S2). On the basis of these characteris-
tics, one might expect that carbonic anhydrase inhibitors
share discontinuous SARs, similar to ribonuclease A.
However, as shown in Figure 3, continuous SARs exist
among sulfonamide derivatives. There is significant corre-
lation between the 2D and 3D similarity (Figures 3A and
3B). Furthermore, dissimilar structures have the greatest
differences in 3D similarity and potency, whereas similar
compounds bind in a similar manner and with comparable
potency (Figures 3A and 3C). Thus, in this case, continu-
ous SARs exist proximal to an ‘‘activity cliff,’’ a boundary
provided by the sulfonamide constraint.
Factor Xa and elastase present examples of active sites
with less stringent requirements for inhibitor binding than
ribonuclease A or carbonic anhydrase II. As shown in
Figure 4A, the majority of factor Xa inhibitors are relatedr Ltd All rights reserved
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Heterogeneous SARs and Variable Activity LandscapesFigure 2. Ribonuclease A Inhibitors
(A) Comparison of 2D and 3D similarity. Each
dot represents values of a pairwise com-
parison of two inhibitors. Data points are
color-coded according to potency differences
by using a continuous spectrum from black
(smallest potency difference) to red (largest
potency difference). The blue and green arrows
identify the inhibitor pairs shown in (B) and (C),
respectively. The red box indicates inhibitors
with similar structures that adopt very different
binding modes. The correlation coefficient of
2D and 3D similarity is 0.58.
(B) Examples of similar inhibitors that bind very
differently in the ribonuclease A active site. On
the left side, the 2D structure of the inhibitors is
shown. On the right, the same inhibitors are
shown in their relative binding conformations
and orientations after optimal superposition
of the enzyme a carbon atoms.
(C) Examples of compounds with very similar
binding modes but dramatic differences in
potency.Chemistry & Biology 14, 489–497, May 2007 ª2007 Elsevier Ltd All rights reserved 491
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Heterogeneous SARs and Variable Activity LandscapesFigure 3. Carbonic Anhydrase Inhibitors
(A) Comparison of 2D and 3D similarity (repre-
sented according to Figure 2A). Compounds
with the lowest 2D and 3D similarity have the
greatest differences in potency (lower left).
The green arrows identify the inhibitor pairs
depicted in (C). The correlation coefficient
between 2D and 3D similarity is 0.79.
(B) Direct correlation between 2D and 3D
similarity among sulfonamides. 2D and 3D sim-
ilarity values are reported for pairwise compar-
isons by using the inhibitor on the left as the
reference compound. The 2D and 3D similarity
to the reference compound decreases from left
to right, as indicated by the yellow wedge.
(C) Examples of sulfonamide inhibitors with
significant (top) or limited (bottom) 2D/3D
similarity.492 Chemistry & Biology 14, 489–497, May 2007 ª2007 Elsevier Ltd All rights reserved
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(A) Comparison of 2D and 3D similarity. The red
box indicates inhibitors that adopt similar bind-
ing modes despite limited structural similarity.
The arrow indicates the inhibitor pair shown
in (B). The correlation coefficient between 2D
and 3D similarity is 0.47.
(B) Examples of inhibitors with low 2D but
distinct 3D similarity.by a continuous SAR. In contrast to ribonuclease A, factor
Xa inhibitors display significant structural diversity. There
is detectable correlation between 2D and 3D similarity,
and most similar 2D structures bind very similarly and
with comparable potency. By contrast, the largest differ-
ences in potency are observed among inhibitors with lim-
ited 2D and 3D similarity. A characteristic feature of factor
Xa inhibitors is that structures with very low 2D similarity
(representing distinct chemical scaffolds) can also adopt
very similar binding modes, as illustrated in Figure 4B.
For these inhibitors, matching the shape of the active
site and forming only a few key interactions are of partic-
ular importance for binding (Figure S3).
Next, we studied elastase. At first glance, there is little
correlation between the 2D and 3D similarity of inhibitors
(Figure 5A). However, we identified subsets of elastase in-
hibitors for which 2D and 3D similarity is either strongly or
inversely correlated (Figure 5B). Selected elastase-inhibi-
tor complexes are shown in Figure 6. For a subset of inhib-
itors consisting of peptide derivatives and other com-
pounds, strong correlation between structural and
binding similarity is observed, and compound potency is
found to increase with decreasing 2D/3D similarity
(Figure 5C). Thus, if we consider the most potent com-
pound as a reference point, gradual structural departures
from a preferred inhibitor are accompanied by a gradualChemistry & Biology 14,loss in potency, which represents a prime example of
a continuous SAR. On the other hand, for a series of tri-
fluoro-acetyl (TFA)-dipeptide-anilides with overall compa-
rable potency, 2D and 3D similarities inversely correlate
(Figure 5D). This means that within this series of inhibitors,
decreasingly similar compounds adopt increasingly simi-
lar binding modes, which represents a different type of
a continuous SAR. How can these observations be ratio-
nalized? As shown in Figure 6A, a series of TFA-dipepe-
tide-anilides adopt three distinct binding modes within
the active site of elastase. However, each of these binding
modes can be adopted by 2D diverse inhibitors that pres-
ent their functional groups in spatially corresponding posi-
tions (Figure 6B). Thus, in the case of elastase, different
continuous SARs can be distinguished. Structures of elas-
tase-inhibitor complexes that represent a series of inhibi-
tors with inversely or directly correlated 2D/3D similarity
are shown in Figure S4.
In summary, inhibitor binding to ribonuclease A is gov-
erned by discontinuous SARs, albeit with a remarkable
degree of 3D variability. By contrast, factor Xa inhibitors
present a prototypic example of continuous SARs. In car-
bonic anhydrase II, significant correlation between 2D and
3D similarity within the boundaries of a structural con-
straint is observed, revealing the presence of a continuous
SAR within the limits of a discontinuous one. This situation489–497, May 2007 ª2007 Elsevier Ltd All rights reserved 493
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(A) Comparison of 2D and 3D similarity. The overall correlation between 2D and 3D similarity is 0.31. The blue and green arrows identify the inhibitors
shown in Figures 6A and 6B, respectively.
(B) Identification of subsets of elastase inhibitors in (A) with strong direct (green) or inverse (light blue) correlation between 2D and 3D similarity. The
green dots refer to the subset shown in (C), and the blue dots refer to the subset in (D). The molecules in these subsets were selected because they are
representative data points in linear models of direct and inverse 2D/3D similarity correlation. Correlation coefficients for direct and inverse correlation
are 0.97 and 0.87, respectively.
(C) Direct correlation between 2D and 3D similarity in a subset of elastase inhibitors (represented as in Figure 3B). The most potent compounds have
the lowest 2D and 3D similarity to others.
(D) Inverse correlation between 2D and 3D similarity in another subset of elastase inhibitors (with comparable potency).is representative of heterogeneous SARs and likely ap-
plies to many different binding sites. Finally, in the case
of elastase, different continuous SARs characterize differ-494 Chemistry & Biology 14, 489–497, May 2007 ª2007 Elsevieent series of elastase inhibitors. For one series, there is
significant correlation between 2D and 3D similarity. By
contrast, for another series of inhibitors, 2D and 3Dr Ltd All rights reserved
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Heterogeneous SARs and Variable Activity LandscapesFigure 6. Alternative Binding Modes in
Elastase
(A) Shown are three structurally similar inhibi-
tors that adopt distinct binding modes in the
active site of elastase.
(B) Each of these binding modes is also shared
by inhibitors with limited 2D similarity. As an
example, two inhibitors are shown that adopt
the binding mode shown on the left in (A).similarity is inversely correlated. However, within this se-
ries, 2D similar inhibitors can adopt three distinct binding
modes, each of which is also shared by diverse ligands.
These findings revise current views that similar ligands
generally bind in a very similar way to the same target
[12] and make it possible to directly relate aspects of
molecular similarity to SAR characteristics.
Taken together, our results reveal systematic trends in
the comparison of 2D and 3D similarity and show that
even severe constraints on binding to active sites permit
significant variability of compound-binding modes and
the coexistence of discontinuous and continuous SARs.
Thus, we demonstrate the heterogeneous nature of SARs
in a target-specific activity landscape. Such SAR charac-
teristics were previously proposed to be of crucial impor-
tance for the successful application of molecular-similarity
methods [5]. Moreover, continuous SARs are observed for
distinct active sites, and different continuous SARs that are
dependent on the features of ligands can coexist in an en-
zyme. The picture that emerges from our analysis of four
‘‘classic’’ enzyme targets is that different SARs are not mu-
tually exclusive and are more heterogeneous in nature than
often thought. Even in rugged activity landscapes, contin-
uous regions exist. These findings imply that different
chemical scaffolds with similar activity can likely be identi-
fied for many different protein targets by searching for
continuous regions of activity landscapes through experi-
mental or computational compound screening.Chemistry & Biology 14,SIGNIFICANCE
The study of small-molecule SARs is one of the major
topics in medicinal chemistry, drug design, and chem-
ical biology. However, the relationship between con-
tinuous and discontinuous SARs is currently not well
understood. Here, we have analyzed X-ray structures
of enzyme-inhibitor complexes and corresponding
binding data in order to systematically correlate the
2D and 3D similarity and potency of ligands. Given
the molecular representations we have chosen, we
find that 2D and 3D similarity and compound potency
can be related in previously unobserved ways. These
results provide evidence for the presence of multiple
and heterogeneous SARswithin active sites and activ-
ity landscapes. These findings suggest that it should
be possible to identify small molecules with diverse
structures but similar activity for many enzymes and
probably other target proteins.
EXPERIMENTAL PROCEDURES
Binding conformations and orientations of inhibitors were compared
after optimal superposition of a carbon atoms of all enzyme structures
(Table S1) by using the sequence/structure alignment function of the
Molecular Operating Environment (MOE, Chemical Computing Group,
Inc.; http://www.chemcomp.com/). For the analysis of 2D and 3D
molecular-similarity relationships, molecular descriptors and repre-
sentations are critical parameters. Our calculation of 2D similarity489–497, May 2007 ª2007 Elsevier Ltd All rights reserved 495
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a measure of 2D similarity, the Tanimoto coefficient (Tc) [13] was cal-
culated (see below) using a fingerprint consisting of the publicly avail-
able set of 166 MACCS structural keys (MDL Elsevier; http://www.mdl.
com/). As a measure of 3D similarity, the normalized overlap of atomic
property density functions [14] was calculated (details are provided
below), which takes both conformational and positional differences
into account. Both 2D and 3D similarity values range from 0 to 1. X-
ray structures were taken from PDBbind [9, 10] or from the RCSB Pro-
tein Data Bank [15]. For inhibitors, we only considered experimentally
determined conformations and binding modes, not modeled struc-
tures. Potency values (Ki or KD) for every crystallized inhibitor were
taken from PDBbind or original references and were transformed
into logarithms to the base of 10. Structural representations were gen-
erated with MOE.
Calculation of 2D Similarity
The 2D similarity of two compounds was computed by means of the
Tanimoto coefficient by using the MACCS fingerprints as implemented
in MOE. This publicly available fingerprint contains 166 bits indicating
the presence of specified structural fragments in the molecular graph
representation. The Tc is a similarity measure for fingerprint overlap
and counts the number of bits common to two binary fingerprints
with respect to the total number of bits that are set on in each finger-
print. The Tc for two binary fingerprint representations, A and B, is cal-
culated as follows:
TcðA;BÞ= NAB
NA +NB  NAB; (1)
where NAB is the number of bits that are set on in both fingerprints, and
NA andNB refer to the number of bits that are set on inA andB, respec-
tively. Given this formulation, identical fingerprints have a Tc value of 1,
whereas nonoverlapping fingerprints are assigned a Tc value of 0.
Calculation of 3D Similarity
For the comparison of the conformation and spatial position of two
bound ligands, a property density function was defined for each mol-
ecule, and the normalized overlap of both functions was calculated as
a measure of 3D molecular similarity.
First, a common reference frame was established by superposition
of the protein a carbon atoms by using the sequence/structure align-
ment function of MOE. Then, a property density function for the coor-
dinates of each ligand was defined and calculated as follows. Each
atom is represented by a spherically symmetric Gaussian density func-
tion centered at the position of the atom nucleus; width is determined
by the van der Waals atom radius. The density function of a molecule is
then defined with respect to specified atomic properties by the
weighted sum of the density functions of all atoms present in the mol-
ecule. The atomic Gaussians are weighted with respect to selected
atom properties. We weight the atomic property density by 1 if the
atom has a specified property, and by 0 if not. The four selected prop-
erties are aromaticity, hydrogen-bond acceptor potential, hydrogen-
bond donor potential, and hydrophobicity.
The overlap of the property density functions of two molecules is the
sum of the respective property density functions, which is again
a Gaussian (Figure S5 provides a graphical illustration of the
approach):
FðX;YÞ=
Xm
i =1
Xn
j = 1
wpi w
p
j +w
q
i w
q
j +.
mn
 
a2
2pðr2i + r2j Þ
!3=2
exp
(
 a
2
2

r2i + r
2
j
xi  yj2
)
: ð2Þ
Here, the following definitions apply:
F(X,Y): overlap of property density functions of conformations X
and Y496 Chemistry & Biology 14, 489–497, May 2007 ª2007 ElsevierX,Y: matrices of spatial atom coordinates for the two molecules
with dimension of 3 3 m and 3 3 n, respectively
m, n: numbers of atoms in molecules X and Y, respectively
xi: vector of coordinates of atom i in conformation X
wi
p: weight of atom i with respect to property p:wi
p = 1 if atom i has
property p, otherwise wi
p = 0
a: scaling factor; set to 2 in our calculations
ri: van der Waals radius of atom i
Calculation of the atomic properties was performed with MOE. Atom
properties were determined by pharmacophore types from MOE as
described below.
wi
aromatic = 1 if atom i is in a ring satisfying the Hueckel rule and is
sp2 hybridized
wi
donor = 1 if atom i is in pharmacophore class ‘‘Donor’’ or in class
‘‘Base’’
wi
acceptor = 1 if atom i is in pharmacophore class ‘‘Acceptor’’ or in
class ‘‘Acid’’
wi
hydrophobic = 1 if atom i is in pharmacophore class ‘‘Hydrophobe’’
A final normalization was carried out in order to obtain 3D similarity
values between 0 (distinct spatial arrangement with no common atom
positions) and 1 (identical conformation and position). The final 3D sim-
ilarity values were obtained by dividing the overlap of the molecular
property density functions by the mean self-overlap of the respective
conformations:
FnormðX;YÞ= FðX;YÞ
1
2
½FðX;XÞ+FðY ;YÞ : (3)
Supplemental Data
Supplemental Data include additional structural representations and
a summary of the X-ray structures used in our analysis and are avail-
able at http://www.chembiol.com/cgi/content/full/14/5/489/DC1/.
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